New Research on Biomarkers in Alzheimer’s Continuum
- 1 August 2025
- journal article
- Published by Bentham Science Publishers Ltd. in Reviews on Recent Clinical Trials
- Vol. 20 (3) , 211-231
Abstract
Alzheimer’s disease (AD) is a multifactorial pathology, responsible for neurodegenerative disorders which in more than 60% of patients evolve into dementia. Comprehension of the molecular mechanisms underlying the pathology and the development of reliable diagnostic methods have made new and more effective therapies possible. In recent years, in addition to the classic anticholinesterases (AChEs), which can control the clinical symptoms of the disease, compounds able to reduce deposits of amyloid-β (Aβ) and/or tau (τ) protein aggregates, which are disease- modifying therapeutics (DMTs), have been studied. The results have shown that symptomatic therapy works best when administered in the disease's mild to moderate clinical phase. On the other hand, treatment with DMTs has been found to be more effective in the preclinical stage of AD, when Aβ and τ protein neurofibrillary tangles have not yet been compromised and patients still have a normal quality of life. This innovative approach requires the identification of specific biomarkers predictive of the disease, detectable many years before clinical signs are evident. Biomarkers allow early diagnosis, give indications of the possible development of dementia in the future, and make it possible to study the evolution of the disease. New scenarios, involving different pathways and approaches, could emerge and provide effective therapies to treat the very early stages of the disease and hamper its progression. The specific biomarkers studied so far have been reported here.Keywords
This publication has 224 references indexed in Scilit:
- Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older AdultsJAMA Neurology, 2019
- Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic ImagingJAMA Neurology, 2018
- Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer DiseaseJAMA Neurology, 2017
- Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and TauopathyJAMA Neurology, 2016
- Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease ProgressionJAMA Neurology, 2016
- Selective Worsening of Brain Injury Biomarker Abnormalities in Cognitively Normal Elderly Persons With β-AmyloidosisJAMA Neurology, 2013
- Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer DementiaArchives of General Psychiatry, 2012
- CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive ImpairmentJAMA, 2009
- Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the BrainArchives of Neurology, 2009
- Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older AdultsArchives of Neurology, 2007